BIOLINERX LTD/S (NASDAQ:BLRX) has been assigned a consensus rating of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $3.00.

Several brokerages have recently issued reports on BLRX. Zacks Investment Research raised shares of BIOLINERX LTD/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 14th. Oppenheimer set a $3.00 price target on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a report on Friday, November 9th. ValuEngine raised shares of BIOLINERX LTD/S from a “hold” rating to a “buy” rating in a report on Tuesday, October 16th. Maxim Group reissued a “buy” rating and set a $2.00 price target on shares of BIOLINERX LTD/S in a report on Thursday, November 8th. Finally, HC Wainwright set a $4.00 price objective on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a report on Friday, November 9th.

Shares of BLRX traded up $0.01 during midday trading on Thursday, hitting $0.67. 1,480,208 shares of the stock traded hands, compared to its average volume of 646,678. BIOLINERX LTD/S has a 1-year low of $0.63 and a 1-year high of $1.84. The company has a market cap of $70.39 million, a price-to-earnings ratio of -2.49 and a beta of 0.84.

BIOLINERX LTD/S (NASDAQ:BLRX) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). On average, equities analysts expect that BIOLINERX LTD/S will post -0.22 EPS for the current fiscal year.

An institutional investor recently bought a new position in BIOLINERX LTD/S stock. Fosun International Ltd acquired a new position in BIOLINERX LTD/S (NASDAQ:BLRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX LTD/S as of its most recent SEC filing. 36.01% of the stock is owned by institutional investors and hedge funds.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Recommended Story: Market Capitalization

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.